Logo image of EVH

EVOLENT HEALTH INC - A (EVH) Stock Fundamental Analysis

USA - NYSE:EVH - US30050B1017 - Common Stock

8.775 USD
-0.24 (-2.72%)
Last: 9/15/2025, 12:25:10 PM
Fundamental Rating

2

Taking everything into account, EVH scores 2 out of 10 in our fundamental rating. EVH was compared to 35 industry peers in the Health Care Technology industry. EVH has a bad profitability rating. Also its financial health evaluation is rather negative. EVH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

EVH had negative earnings in the past year.
EVH had a negative operating cash flow in the past year.
In the past 5 years EVH always reported negative net income.
In multiple years EVH reported negative operating cash flow during the last 5 years.
EVH Yearly Net Income VS EBIT VS OCF VS FCFEVH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.52%, EVH is in the better half of the industry, outperforming 65.71% of the companies in the same industry.
With a Return On Equity value of -16.46%, EVH perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
EVH's Return On Invested Capital of 0.13% is fine compared to the rest of the industry. EVH outperforms 65.71% of its industry peers.
Industry RankSector Rank
ROA -7.52%
ROE -16.46%
ROIC 0.13%
ROA(3y)-3.35%
ROA(5y)-7.41%
ROE(3y)-7.16%
ROE(5y)-16.17%
ROIC(3y)N/A
ROIC(5y)N/A
EVH Yearly ROA, ROE, ROICEVH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

EVH has a Operating Margin of 0.15%. This is in the better half of the industry: EVH outperforms 65.71% of its industry peers.
EVH's Gross Margin of 16.36% is on the low side compared to the rest of the industry. EVH is outperformed by 77.14% of its industry peers.
In the last couple of years the Gross Margin of EVH has declined.
Industry RankSector Rank
OM 0.15%
PM (TTM) N/A
GM 16.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.51%
GM growth 5Y-10.71%
EVH Yearly Profit, Operating, Gross MarginsEVH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EVH is destroying value.
EVH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EVH has been increased compared to 5 years ago.
EVH has a worse debt/assets ratio than last year.
EVH Yearly Shares OutstandingEVH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
EVH Yearly Total Debt VS Total AssetsEVH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of 0.88, we must say that EVH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.88, EVH is in line with its industry, outperforming 54.29% of the companies in the same industry.
A Debt/Equity ratio of 0.73 indicates that EVH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.73, EVH is doing worse than 74.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACC0.02
WACC8.48%
EVH Yearly LT Debt VS Equity VS FCFEVH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.01 indicates that EVH should not have too much problems paying its short term obligations.
The Current ratio of EVH (1.01) is worse than 71.43% of its industry peers.
EVH has a Quick Ratio of 1.01. This is a normal value and indicates that EVH is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of EVH (1.01) is worse than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
EVH Yearly Current Assets VS Current LiabilitesEVH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

EVH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -101.71%.
EVH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 220.75% yearly.
Looking at the last year, EVH shows a decrease in Revenue. The Revenue has decreased by -6.71% in the last year.
EVH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.04% yearly.
EPS 1Y (TTM)-101.71%
EPS 3Y220.75%
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)-6.71%
Revenue growth 3Y41.17%
Revenue growth 5Y30.04%
Sales Q2Q%-31.34%

3.2 Future

The Earnings Per Share is expected to grow by 18.08% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.35% on average over the next years.
EPS Next Y-59.63%
EPS Next 2Y-4.7%
EPS Next 3Y5.61%
EPS Next 5Y18.08%
Revenue Next Year-26.38%
Revenue Next 2Y-2.79%
Revenue Next 3Y2.92%
Revenue Next 5Y7.35%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EVH Yearly Revenue VS EstimatesEVH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B
EVH Yearly EPS VS EstimatesEVH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVH. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 14.64 indicates a correct valuation of EVH.
EVH's Price/Forward Earnings ratio is rather cheap when compared to the industry. EVH is cheaper than 91.43% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.73. EVH is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 14.64
EVH Price Earnings VS Forward Price EarningsEVH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EVH is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.22
EVH Per share dataEVH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.7%
EPS Next 3Y5.61%

More info and screens

0

5. Dividend

5.1 Amount

EVH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLENT HEALTH INC - A

NYSE:EVH (9/15/2025, 12:25:10 PM)

8.775

-0.24 (-2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners108.51%
Inst Owner Change1.95%
Ins Owners1.53%
Ins Owner Change2.35%
Market Cap1.03B
Analysts83.33
Price Target15.98 (82.11%)
Short Float %17.55%
Short Ratio5.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.11%
Min EPS beat(2)-226.45%
Max EPS beat(2)-37.77%
EPS beat(4)0
Avg EPS beat(4)-171.4%
Min EPS beat(4)-332.96%
Max EPS beat(4)-37.77%
EPS beat(8)4
Avg EPS beat(8)-30.3%
EPS beat(12)7
Avg EPS beat(12)11.34%
EPS beat(16)11
Avg EPS beat(16)446.31%
Revenue beat(2)1
Avg Revenue beat(2)-0.11%
Min Revenue beat(2)-4.24%
Max Revenue beat(2)4.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)4.03%
Revenue beat(8)4
Avg Revenue beat(8)0.39%
Revenue beat(12)6
Avg Revenue beat(12)0.07%
Revenue beat(16)9
Avg Revenue beat(16)0.78%
PT rev (1m)-12.67%
PT rev (3m)-12.67%
EPS NQ rev (1m)24.21%
EPS NQ rev (3m)1.5%
EPS NY rev (1m)-25.25%
EPS NY rev (3m)-37.42%
Revenue NQ rev (1m)-4.49%
Revenue NQ rev (3m)-11.9%
Revenue NY rev (1m)-8.38%
Revenue NY rev (3m)-8.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.64
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB N/A
EV/EBITDA 14.22
EPS(TTM)-0.02
EYN/A
EPS(NY)0.6
Fwd EY6.83%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS18.69
BVpS9.57
TBVpS-5.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.52%
ROE -16.46%
ROCE 0.18%
ROIC 0.13%
ROICexc 0.14%
ROICexgc 1.94%
OM 0.15%
PM (TTM) N/A
GM 16.36%
FCFM N/A
ROA(3y)-3.35%
ROA(5y)-7.41%
ROE(3y)-7.16%
ROE(5y)-16.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.51%
GM growth 5Y-10.71%
F-Score2
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Debt/EBITDA 7.49
Cap/Depr 28.07%
Cap/Sales 1.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z 0.88
F-Score2
WACC8.48%
ROIC/WACC0.02
Cap/Depr(3y)38.35%
Cap/Depr(5y)41.66%
Cap/Sales(3y)1.98%
Cap/Sales(5y)2.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.71%
EPS 3Y220.75%
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y-59.63%
EPS Next 2Y-4.7%
EPS Next 3Y5.61%
EPS Next 5Y18.08%
Revenue 1Y (TTM)-6.71%
Revenue growth 3Y41.17%
Revenue growth 5Y30.04%
Sales Q2Q%-31.34%
Revenue Next Year-26.38%
Revenue Next 2Y-2.79%
Revenue Next 3Y2.92%
Revenue Next 5Y7.35%
EBIT growth 1Y239.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year302.75%
EBIT Next 3Y82.87%
EBIT Next 5Y55.33%
FCF growth 1Y-203.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-233.8%
OCF growth 3Y-21.47%
OCF growth 5YN/A